Overall, these results suggest that the DT2216 + AZ8055 combination may be a promising therapeutic strategy, particularly against BCL-XL/MCL-1 co-dependent SCLC, and therefore this combination could potentially be tested in clinical trials in the future. This evidence concerns the gene BCL2L1 and small cell lung carcinoma.